Resomer® and Lactel® Portfolio of Excipients for Parenteral Controlled Release by Evonik

A broad, versatile range of standard, custom and specialized parenteral excipients

The RESOMER® and LACTEL® portfolios provide an industry-leading selection of functional excipients for parenteral controlled release. As an expert provider of custom and specialized parenteral excipients, we offer an innovative and highly versatile portfolio which supports local and systemic delivery of complex parenteral formulations including microparticles, in-situ depots, nanoparticles and drug loaded implants.

Our RESOMER® portfolio has been delivering safety, biocompatibility and supply security to companies with complex parenteral drug products for more than 30 years. In 2020, Evonik acquired the LACTEL® absorbable polymers portfolio—first commercialized in 1987— from DURECT Corporation. Together, these absorbable polymers have been defining polymer quality for decades and find application in numerous FDA-approved pharmaceutical products.

Both portfolios are 100 percent bioresorbable, completely metabolized by the body (hence, bioabsorbable), and ideal for terminal sterilization. With a shelf life exceeding five years, RESOMER® and LACTEL® are highly suitable for use with small molecules, peptides, proteins and other substances. Both are supplied from modern, established manufacturing sites in the U.S. and Germany – ensuring extensive options for dual sourcing and supply security.

Resomer® – Pure Polymers, Pure Excellence – Decades Of Setting The Standard

The RESOMER® standard catalog of parenteral excipients includes Poly (lactide) and Poly (lactide-co-glycolide) polymers. These are supplied in varying molecular weights and monomer compositions that can be tailored to adjust degradation times from a few weeks up to 18 months. RESOMER® stands for high quality, and the portfolio includes a selection of customizable options.

• RESOMER® Select is the world’s leading brand of custom parenteral excipients. A range of characteristics can be tailored including monomers, polymer composition and microstructure, particle size distribution, end groups, molecular weight, and inherent viscosity (IV).
• RESOMER® Precise enables extremely tight product specifications including the control of inherent viscosity to within a narrow range of ≤ ± 0.02 dL/g, which equates to between four and ten times more precise than equivalent parenteral excipients.
• RESOMER® Zero is purified through a proprietary purification process that provides polymeric parenteral excipients with residual tin content of less than 1 ppm.

Lactel® – Meeting Your Need For Price Sensitive Applications And Small Quantities

The LACTEL® portfolio consists of over 20 standard Poly (lactide) and Poly (lactide-co-glycolide) polymers, including linear ester and acid terminated polymers, and a branched glucose star polymer. For projects where cost of goods is of paramount importance, LACTEL® is your brand of choice. Our streamlined manufacturing processes ensure that, from start to finish, LACTEL® polymer quality is consistent from research to commercial scale. The broad range of standard products are available in small pack sizes with a 20-gram minimum order quantity. Whether focusing on generic, veterinary, academic research, or pharmaceutical applications, LACTEL® is available to meet a variety of projects’ time- and cost-sensitive polymer needs.

Read the original article here

Source: Evonik, website RESOMER® AND LACTEL® PORTFOLIO OF EXCIPIENTS FOR PARENTERAL CONTROLLED RELEASE – Evonik Industries

See our next webinar:

“Rethinking the development of controlled release formulations and manufacturing processes”

Date: 30th of April, Time: 3:00 pm (Amsterdam, Berlin)

WEBINAR REGISTRATION HERE